KMT2A-REARRANGED
Clinical trials for KMT2A-REARRANGED explained in plain language.
Never miss a new study
Get alerted when new KMT2A-REARRANGED trials appear
Sign up with your email to follow new studies for KMT2A-REARRANGED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo tackles tough leukemia
Disease control Not yet recruitingThis early-phase study tests two drugs, blinatumomab and revumenib, given together to adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A rearrangement. The main goal is to find a safe dose and understand si…
Matched conditions: KMT2A-REARRANGED
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo targets tough leukemia in early trial
Disease control Not yet recruitingThis early-phase study tests two oral drugs, ziftomenib and mezigdomide, given together to adolescents and adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial focuses on people whose leukemia has specific genetic changes (KMT2A rea…
Matched conditions: KMT2A-REARRANGED
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC